Inc. (NASDAQ:MNMD – Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)的首席法务官Mark ...

Charles Schwab Investment Management Inc. grew its holdings in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)的首席医疗官Dan Karlin最近出售了公司6,643股普通股。该公司是一家市值5.02亿美元的生物科技公司，其股票在过去一年中上涨超过100%。根据 InvestingPro 的数据，分析师对MNMD保持看好态度，多项关键指标显示公司财务状况良好。这次出售是在2024年12月26日执行的，属于根据规则10b5- ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized ...

1 Day MNMD 3.39% DJIA 0.91% Russell 2K 1.00% Health Care/Life Sciences 2.09% ...

Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the ...

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Major Depressive Disorder.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders ...

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders ...